Posters
Clinical experience with multifocal segmented bi-aspheric lens SBL-3 with 400 eyes on file
Poster Details
First Author: R.Zugar CZECH REPUBLIC
Co Author(s): A. Janeková J. Pašta M. Janek
Abstract Details
Purpose:
To evaluate efficacy, predictability, safety and subjective outcomes of rotationally asymmetric multifocal segmented bi-aspheric intraocular lens in patients with cataract and clear lens extraction.
Setting:
Eye Centre Prague, Prague, Czech Republic.
Methods:
A prospective study based on evaluation of 400 eyes of 204 patients was done in 4 years. Both cataract and clear lens extraction patients were included. SBL-3 is hydrophilic acrylic presbyopia correcting lens. The availability of the lens is in 0.25 diopter power increments. The IOL power was calculated using SRK/T formula. Patients were evaluated postoperatively for distance, intermediate (70cm) and near visual acuity. A satisfaction questionnaire was administered 3 months after surgery. Patients were asked about photopic phenomenon such as glare and halos and evaluated spectacle independence in everyday activities.
Results:
The percentage of patients who achieved uncorrected distance visual acuity of 0,8 or better was 90%, the percentage of patients who achieved 1,0 or better was 75%. In evaluation of intermediate visual acuity 81% of patients achieved uncorrected intermediate visual acuity 0,8 or better and 40% of patients achieved 1,0 or better. The uncorrected near visual acuity was 0,8 or better in 88% of patients and 1,0 or better in 60% of patients.
Subjectively patients report low levels of photopic phenomenons and high levels of spectacle independence in everyday activities for all distances.
Conclusions:
SBL-3 IOLs report excelent visual outcomes and low levels of photopic phenomenons. Patients receiving SBL-3 in current study attained very good uncorrected visual acuity at all range of distances and spectacle independence. Also preoperatively myopic patients that used to read without spectacles were very satisfied with the near vision after surgery.
Financial Disclosure:
None